CULLINAN THERAPEUTICS, INC. Proceeds from Common Stock Issued
CULLINAN THERAPEUTICS, INC. (CGEM) reported Proceeds from Common Stock Issued of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-03-10
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2024 was $262.65M, a 584.20% increase from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2023 was $38.39M.
- CULLINAN THERAPEUTICS, INC. proceeds from issuance of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $0.00 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | ||||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $262.65M 10-K · filed 2026-03-10 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $262.65M 10-Q · filed 2025-11-06 | |||||
| 2024-06-30 | $262.65M 10-Q · filed 2025-08-07 | ||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $38.42M derived: sum of 3 quarters · filed 2025-02-27 | $38.39M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $38.42M derived: sum of 2 quarters · filed 2023-11-08 | $38.39M 10-Q · filed 2023-11-08 | $38.39M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2023-06-30 | $38.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $38.39M 10-Q · filed 2023-08-10 | $38.39M derived: sum of 3 quarters · filed 2024-03-14 | $38.39M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2023-03-31 | -$36.00K 10-Q · filed 2023-05-11 | -$36.00K derived: sum of 2 quarters · filed 2024-03-14 | -$36.00K derived: sum of 3 quarters · filed 2024-03-14 | -$1.62M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | -$1.59M derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 | $6.02M 10-K · filed 2023-03-09 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$1.59M derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $5.83M 10-Q · filed 2022-11-14 | $2.70M derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | -$1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $4.40M 10-Q · filed 2022-08-10 | $2.70M derived: sum of 3 quarters · filed 2023-08-10 | $3.28M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $1.59M 10-Q · filed 2023-05-11 | $4.29M derived: sum of 2 quarters · filed 2023-05-11 | $4.87M derived: sum of 3 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.28M derived: sum of 2 quarters · filed 2023-03-09 | $3.28M 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $579.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $579.00K 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | ||||||
| 2020-12-31 | $131.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $131.20M derived: sum of 2 quarters · filed 2022-03-17 | $131.20M derived: sum of 3 quarters · filed 2022-03-17 | $145.45M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $14.25M 10-Q · filed 2021-11-09 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $14.25M 10-Q · filed 2021-08-10 | |||||
| 2020-03-31 | $14.25M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |